

Mark A. Stead,<sup>a</sup> Stephen B. Carr<sup>b</sup>  
and Stephanie C. Wright<sup>a\*</sup><sup>a</sup>Molecular Cell Biology Research Group,  
Garstang Building, Institute of Molecular and  
Cellular Biology, Faculty of Biological Sciences,  
University of Leeds, Leeds LS2 9JT, England, and<sup>b</sup>Membrane Protein Laboratory, Diamond Light  
Source, Harwell Science and Innovation  
Campus, Chilton, Didcot OX11 0DE, England

Correspondence e-mail: s.c.wright@leeds.ac.uk

Received 13 March 2009

Accepted 1 April 2009

**PDB Reference:** Nac1 POZ domain, 3ga1,  
r3ga1sf.


## Structure of the human Nac1 POZ domain

Nac1 is a POZ-domain transcription factor that is involved in the self-renewal of embryonic stem cells. It is overexpressed in ovarian serous carcinoma and targeting the interactions of its POZ domain is a potential therapeutic strategy. Nac1 lacks a zinc-finger DNA-binding domain and thereby differs from most other POZ-domain transcription factors. Here, the crystal structure of the Nac1 POZ domain at 2.1 Å resolution is reported. The Nac1 POZ domain crystallized as a dimer in which the interaction interfaces between subunits resemble those found in the POZ-zinc finger transcription factors. The organization of the Nac1 POZ-domain core resembles reported POZ-domain structures, whereas the C-terminus differs markedly. The C-terminal  $\alpha$ -helix of the Nac1 POZ domain is shorter than that observed in most other POZ-domain transcription factors; variation in the organization of this region may be a general feature of POZ-domain structures.

## 1. Introduction


Nac1 is a POZ-domain protein that was originally characterized as a cocaine-inducible gene product in the nucleus accumbens of rat brain (Cha *et al.*, 1997). It was initially shown to function in the behavioural responses to psychostimulants (Mackler *et al.*, 2000), although has subsequently been implicated in diverse physiological processes. Nac1 mediates the translocation of the ubiquitin–proteasome (UPS) complex from the nucleus into neuronal dendritic spines, thereby regulating proteolysis during synaptic remodelling (Shen *et al.*, 2007). Nac1 also acts as a transcriptional repressor in both neuronal and non-neuronal cells (Korutla *et al.*, 2002, 2005; Nakayama *et al.*, 2007); it interacts with the homeodomain protein Nanog and is thus a central component of the transcription-factor network that maintains the pluripotency of embryonic stem cells (Wang *et al.*, 2006). Levels of Nac1 are elevated in advanced ovarian serous carcinoma and cervical carcinoma (Nakayama *et al.*, 2006; Yeasmin *et al.*, 2008); in ovarian cancer, expression is particularly high in recurrent disease and in effusions and is thought to contribute to the development of resistance to chemotherapy (Davidson *et al.*, 2007; Ishibashi *et al.*, 2008). Artificial knock-down of Nac1 resulted in the apoptosis of ovarian cancer cell lines and rescued their sensitivity to chemotherapy, suggesting that this protein may be a potential therapeutic target.

POZ (poxvirus and zinc finger; also known as BTB, bric-à-brac, tramtrack and broad complex) domains are protein–protein interaction motifs that are found in over 200 human proteins (reviewed in Stogios *et al.*, 2005). POZ-domain proteins function in a wide range of biological activities, including transcription, ion-channel gating, cytoskeletal dynamics and protein degradation *via* the ubiquitin–proteasome (UPS) system. Approximately 40 transcription factors contain N-terminal POZ domains (POZ-TFs); many of these play roles in development and the deregulation of POZ-TF expression has been observed in several human cancers (reviewed in Kelly & Daniel, 2006). Most POZ-TFs contain C<sub>2</sub>H<sub>2</sub> zinc-finger or basic leucine-



zipper DNA-binding domains; however, Nac1 is distinct and does not contain any characterized DNA-binding motifs. The mechanism by which Nac1 interacts with DNA is not known, although target genes have been identified by chromatin immunoprecipitation and microarray approaches (Kim *et al.*, 2008). POZ domains mediate the homodimerization of POZ-zinc finger transcription factors and also direct the formation of higher order oligomers and heteromeric POZ–POZ complexes; the oligomeric organization of Nac1 has not been characterized. Crystal structures of the POZ domains from the zinc-finger proteins PLZF (promyelocytic leukaemia zinc finger; Ahmad *et al.*, 1998; Li *et al.*, 1999), BCL6 (B-cell lymphoma 6; Ahmad *et al.*, 2003; Ghetu *et al.*, 2008; Stead *et al.*, 2008) and LRF (leukaemia/lymphoma-related factor; Schubot *et al.*, 2006; Stogios *et al.*, 2007) revealed domain-swapped homodimers that are thought to represent the biologically active unit. In contrast, the Miz-1 (Myc-interacting zinc-finger protein 1) POZ domain crystallized as a tetramer in which two POZ dimers interact *via* a  $\beta$ -sheet region (Stead *et al.*, 2007); this tetrameric organization was also observed in solution, suggesting that this interface may be important in the higher order homo- and hetero-oligomerization of the POZ-TFs *in vivo*.

POZ domains interact with non-POZ partners in a highly specific manner. The POZ-TF POZ domains recruit transcriptional co-regulators: for example, BCL6 binds the co-repressors BCoR (BCL6-interacting co-repressor), SMRT (silencing mediator for retinoid and thyroid hormone receptors) and NCoR (nuclear receptor co-repressor), whereas Nac1 recruits CoREST (co-repressor of RE1-silencing transcription factor, also known as RCoR; Korutla *et al.*, 2007). The Nac1 POZ domain also interacts with cullin 3, consistent with its role in the UPS system (Shen *et al.*, 2007). Targeting the interactions of POZ domains with their transcriptional co-repressors is a strategy for the treatment of tumours associated with deregulated POZ-TF expression. Crystal structures of BCL6 in association with BCoR (Ghetu *et al.*, 2008) and SMRT (Ahmad *et al.*, 2003) peptides led to the design of inhibitors that interfere with co-repressor recruitment; these inhibitors induced the apoptosis of diffuse large B-cell lymphoma (DLBCL) tumour cells that overexpress BCL6 and are promising therapeutic agents (Parekh *et al.*, 2008). Targeting the interactions of the Nac1 POZ domain is a potential strategy for the treatment of ovarian cancer; here, we report the crystal structure of the Nac1 POZ domain to 2.1 Å resolution.



**Figure 1** Structure of the Nac1 POZ domain. (a) Sequence alignment of the Nac1, Miz-1, PLZF, BCL6 and LRF POZ domains. Sequences were aligned using *ClustalW*. The observed secondary-structure elements of the Nac1 POZ domain are indicated, with  $\alpha$ -helices in orange and  $\beta$ -sheets in green. The residues of  $\alpha 6$  in the Miz-1, PLZF, BCL6 and LRF POZ domains are shown in pale orange. (b) Ribbon representation of the Nac1 POZ-domain dimer. The position of the F98D mutation is shown with an asterisk. The secondary-structure elements of chain A are indicated, together with  $\beta 1'$  and  $\beta 5'$  of chain B.

**Table 1**

Data-collection and processing statistics.

Values in parentheses are for the highest resolution shell (2.1–2.21 Å).

Crystal parameters	
Space group	$P4_12_12$
Unit-cell parameters (Å, °)	$a = 57.69$ , $b = 57.69$ , $c = 172.60$ , $\alpha = 90$ , $\beta = 90$ , $\gamma = 90$
Data collection	
Resolution (Å)	47.96–2.10 (2.21–2.10)
Wavelength (Å)	0.9763
$R_{\text{merge}}^{\dagger}$ (%)	10.3 (50.6)
$R_{\text{p.i.m.}}^{\ddagger}$ (%)	4.3 (20.5)
$\langle I/\sigma(I) \rangle$	13.5 (4.0)
No. of unique reflections	17928
Multiplicity	6.7 (7.0)
Completeness (%)	100 (100)
Refinement	
Resolution (Å)	2.1
$R\%$	0.206
$R_{\text{free}}^{\S}$ (%)	0.241
R.m.s.d. stereochemistry $^{\dagger\dagger}$	
Bond lengths (Å)	0.114
Bond angles (°)	1.294
No. of protein atoms	1857
No. of water molecules	107
Average $B$ factor (Å <sup>2</sup> )	18.09
Ramachandran analysis $^{\ddagger\dagger\dagger}$ (%)	
Favoured	96.2
Allowed	100.0
Disallowed	0

$^{\dagger} R_{\text{merge}} = \sum_{hkl} \sum_i |I_i(hkl) - \langle I(hkl) \rangle| / \sum_{hkl} \sum_i I_i(hkl)$ , where  $I_i(hkl)$  is the integrated intensity of a given reflection and  $\langle I(hkl) \rangle$  is the mean intensity of multiple corresponding symmetry-related reflections.  $^{\ddagger} R_{\text{p.i.m.}} = \sum_{hkl} [1/(N-1)]^{1/2} \sum_i |I_i(hkl) - \langle I(hkl) \rangle| / \sum_{hkl} \sum_i I_i(hkl)$ , where  $I_i(hkl)$  is the integrated intensity of a given reflection,  $\langle I(hkl) \rangle$  is the mean intensity of multiple corresponding symmetry-related reflections and  $N$  is the multiplicity of a given reflection.  $^{\S} R = \sum_{hkl} (|F_o| - |F_c|) / \sum_{hkl} |F_o|$ , where  $F_o$  and  $F_c$  are the observed and calculated structure factors, respectively.  $^{\dagger\dagger} R_{\text{free}}$  is the same as  $R$  but calculated using 5% random data excluded from the refinement.  $^{\dagger\dagger\dagger}$  R.m.s.d. stereochemistry is the deviation from ideal values.  $^{\ddagger\dagger\dagger}$  Ramachandran analysis was carried out using *MolProbity* (Davis *et al.*, 2007).

## 2. Materials and methods

### 2.1. Cloning

A DNA fragment encoding the Nac1 POZ domain (Nac1 residues 2–125) was amplified by PCR from a human placental cDNA library and inserted into the expression vector pGEX-6P-1 (GE Healthcare). The POZ-domain F98D mutant was generated by PCR with Phusion High-Fidelity DNA polymerase (Finnzymes) using the oligonucleotides ATGAACGTGGGCGACCAGGACCTGCTCATGTACACG-GCT and GCTCAGCCGGCCCGTGTAGCAGAAGCTGAGGTA-CTG.

### 2.2. Protein expression and purification

GST-fusion proteins were expressed in *Escherichia coli* BL21 (DE3) pLysS. Bacteria were cultured in 2TY at 310 K to an OD<sub>600nm</sub> of 0.8. Expression of recombinant protein was then induced with 0.1 mM IPTG at 289 K for 16 h. Cells were lysed and fusion proteins were bound to glutathione-Sepharose 4B (GE Healthcare). The N-terminal GST tag was removed by cleavage with PreScission protease in 20 mM Tris-HCl, 75 mM NaCl, 5 mM DTT pH 7.5. The Nac1 POZ domain was further purified by gel-filtration chromatography in 20 mM Tris-HCl, 150 mM NaCl, 5 mM DTT, 5% glycerol pH 8.6 and concentrated to 14 mg ml<sup>-1</sup> using Amicon centrifugal concentrators (Millipore).

### 2.3. Crystallization

Crystals of the Nac1 POZ domain were grown by sitting-drop vapour diffusion at 291 K by mixing 2 µl protein solution

(14 mg ml<sup>-1</sup>) with 2 µl reservoir solution (6 M ammonium nitrate, 0.1 M bis-tris propane pH 7.5). Large crystals were typically obtained after 48 h. Crystals were mounted in a nylon cryoloop (Hampton Research) and transferred to mother liquor supplemented with 20% glycerol for 30 s before being flash-frozen in liquid nitrogen.


### 2.4. Data collection, structure determination and refinement

X-ray diffraction data were collected under a nitrogen-gas stream at 100 K on beamline I03 at the Diamond Light Source (Didcot, England). Data reduction was performed using *iMOSFLM* and *SCALA* (Leslie, 1992; Collaborative Computational Project, Number 4, 1994). The structure was solved using the *MrBUMP* molecular-replacement pipeline (Keegan & Winn, 2007); the *MrBUMP* solution was obtained using a *MOLREP*-generated search model from the LRF POZ domain (PDB code 2if5) with *Phaser* as the molecular-replacement program (McCoy *et al.*, 2005). A model was built using *ARP/wARP* (Perrakis *et al.*, 1999); this was followed by iterative model building and refinement in *Coot* (Emsley & Cowtan, 2004) and *REFMAC* (Murshudov *et al.*, 1997), including TLS refinement with three TLS groups per POZ-domain monomer. The stereochemistry was analysed with *PROCHECK* (Laskowski *et al.*, 1993) and *MolProbity* (Davis *et al.*, 2007) and structure superpositions were calculated using the *SUPERPOSE* server (Maiti *et al.*, 2004); the PDB entries used for superpositions were Miz-1, 2q81; BCL6, 1r28; PLZF, 1buo; LRF, 2nn2. Images of protein structures were prepared using *PyMOL* (DeLano, 2002).

## 3. Results and discussion

Expression of the wild-type human Nac1 POZ domain in *E. coli* produced highly insoluble recombinant protein, even upon attempted optimization of the expression and purification protocols. The Nac1 POZ-domain sequence is 38% identical to that of Miz-1; since recombinant Miz1 POZ domain is highly soluble, we used the crystal structure of the Miz1 POZ domain to predict surface residues that might contribute to the insolubility of Nac1. Mutation of a single surface hydrophobic residue (F98D; Fig. 1a) enabled the purification of highly soluble recombinant Nac1 POZ domain. This mutation does not reside near residues that have been implicated either in POZ-domain oligomerization or in the recruitment of transcriptional co-repressors. The F98D Nac1 POZ domain was crystallized and the structure was solved by molecular replacement and refined to  $R = 20.63\%$ ,  $R_{\text{free}} = 24.09\%$  at 2.1 Å resolution (Table 1; Fig. 1b).

Nac1 is a distinct POZ-domain transcription factor that does not contain a characteristic zinc-finger or basic leucine-zipper DNA-binding domain. The POZ domains of the individual POZ-zinc finger transcription factors have approximately the same degree of homology to each other as they do to Nac1, suggesting similar timescales of evolutionary divergence (Fig. 1a). The Nac1 POZ domain crystallized as a domain-swapped dimer whose interfaces closely resemble those reported in the POZ domains of the POZ-zinc finger proteins BCL6, PLZF and LRF (Fig. 1b). A central hydrophobic interface that buries 1018 Å<sup>2</sup> surface area per monomer is formed by the tight packing of helices  $\alpha_1$ ,  $\alpha_2$  and  $\alpha_3$ , whereas two  $\beta$ -strand interfaces that bury an additional 947 Å<sup>2</sup> per monomer are formed by the interaction of  $\beta_1$  of one subunit with  $\beta_5$  of the other (Fig. 1b). It is therefore likely that Nac1 functions biologically as an obligate homodimer in a manner resembling the POZ-zinc finger proteins. The organization of secondary-structure elements in the centre of the Nac1 POZ dimer ( $\beta_1$ – $\alpha_5$ ) is the same as in reported POZ structures; compared with Nac1, the r.m.s.d. values of C $^{\alpha}$ -atom positions are 1.62 Å for BCL6,



**Figure 2**

Superposition of POZ-domain structures. (a) Stereo-image of POZ-domain C $\alpha$ -atom superposition for Nacl (red), BCL6 (green), PLZF (yellow) and LRF (blue). The accession codes of the PDB entries used for superposition were BCL6, 1r28; PLZF, 1buo; LRF, 2nn2. (b) Superposition of the BCL6 (pale green) and Nacl (pale pink) POZ domains. The  $\alpha 5$  and  $\alpha 6$  regions of chain B are highlighted in green (BCL6) and red (Nacl).

2.19 Å for Miz-1, 2.31 Å for PLZF and 2.37 Å for LRF. Conserved residues that constitute a charged pocket in the POZ-TF POZ domains are also present in Nacl (Asp31 and Arg45); this region is thought to be important in transcriptional repression in BCL6 and PLZF, although the mechanism involved is unknown (Melnick *et al.*, 2002).

The organization of the C-terminus in the Nacl POZ domain differs from that in the reported BCL6, LRF, PLZF and Miz-1 POZ-domain structures (Fig. 2). The C-terminal residues of the latter POZ domains form a 12-residue  $\alpha$ -helix ( $\alpha 6$ ) that lies adjacent to  $\alpha 5$  on the outside of the molecule. The corresponding helix in Nacl is extremely short and the C-terminal residues are unstructured and diverge away from  $\alpha 5$  to interact with the lower  $\beta 1$ – $\beta 5'$  sheet. These C-terminal residues have the highest B factors of the Nacl POZ-domain crystal structure in chain B and are disordered in chain A. The residues corresponding to  $\alpha 6$  constitute the least conserved sequences among the POZ domains of the POZ-TFs and the  $\alpha$ -helical propensities of the amino acids in the middle of this region differ greatly. The POZ-domain  $\alpha 6$  helix of the zinc-finger transcriptional repressor Kaiso (also known as ZBTB33; PDB code 3fkc) is also extremely short; the low  $\alpha$ -helical propensity of the Nacl and Kaiso residues in the middle of  $\alpha 6$  (glycine in Nacl; glycine and proline in Kaiso) may contribute to this structural feature. The elongin C proteins contain a POZ domain that lacks an entire  $\alpha 6$  helix; interestingly, the  $\alpha 5$  helix of elongin C is involved in its interaction with the VHL protein in a manner that would not be compatible with the presence of a POZ-domain  $\alpha 6$  helix in its classical location (Stebbins *et al.*, 1999). Variation in the length of the C-terminal  $\alpha 6$  helix may therefore be a

general feature of POZ domains, although its biological relevance in the POZ-TFs is unknown.

The recruitment of transcriptional co-repressors to the POZ-TF POZ domains is highly specific: for example, BCL6 interacts with SMRT and BCoR in a mutually exclusive manner, whereas neither of these co-repressors bind to LRF or Nacl. The residues of SMRT and BCoR that interact with BCL6 share no sequence homology, although both bind to the POZ-domain lateral grooves that run across  $\beta 1$  and up through the dimerization interface. The POZ-domain dimer recruits two co-repressor molecules symmetrically; contacts are mediated by residues in  $\beta 1$ ,  $\alpha 1$ ,  $\alpha 2$ ,  $\alpha 3$  and  $\alpha 6$  of both POZ subunits and involve the rearrangement of some amino-acid side chains. Conserved interactions of the BCL6 POZ domain with SMRT and BCoR involve the main-chain atoms of the co-repressor, whereas nonconserved interactions are mediated by the side chains. The most important BCL6 residues that interact with SMRT and BCoR are notably not conserved in the Nacl POZ domain: BCL6 residues Gln10, Arg13, Arg24, His116, Arg28 and Tyr58 are replaced by amino acids of different charge in Nacl, with the equivalent positions being Glu8, Asn11, Glu22, Glu114, Gln26 and Arg56, respectively. It will now be relevant to determine the residues that direct the specific interactions of the Nacl POZ domain with the transcriptional co-repressor CoREST.

This work was funded by Yorkshire Cancer Research and by a BBSRC studentship to MAS. We thank the staff at the Diamond

Light Source (Didcot, UK) for assistance during X-ray data collection.

## References

- Ahmad, K. F., Engel, C. K. & Privé, G. G. (1998). *Proc. Natl Acad. Sci. USA*, **95**, 12123–12128.
- Ahmad, K. F., Melnick, A., Lax, S., Bouchard, D., Liu, J., Kiang, C. L., Mayer, S., Takahashi, S., Licht, J. D. & Privé, G. G. (2003). *Mol. Cell*, **12**, 1551–1564.
- Cha, X. Y., Pierce, R. C., Kalivas, P. W. & Mackler, S. A. (1997). *J. Neurosci.* **17**, 6864–6871.
- Collaborative Computational Project, Number 4 (1994). *Acta Cryst.* **D50**, 760–763.
- Davidson, B., Berner, A., Trope, C. G., Wang, T. L. & Shih, I.-M. (2007). *Hum. Pathol.* **38**, 1030–1036.
- Davis, I. W., Leaver-Fay, A., Chen, V. B., Block, J. N., Kapral, G. J., Wang, X., Murray, L. W., Arendall, W. B. III, Snoeyink, J., Richardson, J. S. & Richardson, D. C. (2007). *Nucleic Acids Res.* **35**, W375–W383.
- DeLano, W. L. (2002). *The PyMol Molecular Graphics System*. <http://www.pymol.org>.
- Emsley, P. & Cowtan, K. (2004). *Acta Cryst.* **D60**, 2126–2132.
- Ghetu, A. F., Corcoran, C. M., Cerchiatti, L., Bardwell, V. J., Melnick, A. & Privé, G. G. (2008). *Mol. Cell*, **29**, 384–391.
- Ishibashi, M., Nakayama, K., Yeasmin, S., Katagiri, A., Iida, K., Nakayama, N., Fukumoto, M. & Miyazaki, K. (2008). *Clin. Cancer Res.* **14**, 3149–3155.
- Keegan, R. M. & Winn, M. D. (2007). *Acta Cryst.* **D63**, 447–457.
- Kelly, K. F. & Daniel, J. M. (2006). *Trends Cell Biol.* **16**, 578–587.
- Kim, J., Chu, J., Shen, X., Wang, J. & Orkin, S. H. (2008). *Cell*, **132**, 1049–1061.
- Korutla, L., Degnan, R., Wang, P. & Mackler, S. A. (2007). *J. Neurochem.* **101**, 611–618.
- Korutla, L., Wang, P. J., Lewis, D. M., Neustadter, J. H., Stromberg, M. F. & Mackler, S. A. (2002). *Neuroscience*, **110**, 421–429.
- Korutla, L., Wang, P. J. & Mackler, S. A. (2005). *J. Neurochem.* **94**, 786–793.
- Laskowski, R. A., MacArthur, M. W., Moss, D. S. & Thornton, J. M. (1993). *J. Appl. Cryst.* **26**, 283–291.
- Leslie, A. G. W. (1992). *Jnt CCP4/ESF-EACBM Newsl. Protein Crystallogr.* **26**.
- Li, X., Peng, H., Schultz, D. C., Lopez-Guisa, J. M., Rauscher, F. J. III & Marmorstein, R. (1999). *Cancer Res.* **59**, 5275–5282.
- Mackler, S. A., Korutla, L., Cha, X. Y., Koebbe, M. J., Fournier, K. M., Bowers, M. S. & Kalivas, P. W. (2000). *J. Neurosci.* **20**, 6210–6217.
- Maiti, R., Van Domselaar, G. H., Zhang, H. & Wishart, D. S. (2004). *Nucleic Acids Res.* **32**, W590–W594.
- McCoy, A. J., Grosse-Kunstleve, R. W., Storoni, L. C. & Read, R. J. (2005). *Acta Cryst.* **D61**, 458–464.
- Melnick, A., Carlile, G., Ahmad, K. F., Kiang, C. L., Corcoran, C., Bardwell, V., Privé, G. G. & Licht, J. D. (2002). *Mol. Cell Biol.* **22**, 1804–1818.
- Murshudov, G. N., Vagin, A. A. & Dodson, E. J. (1997). *Acta Cryst.* **D53**, 240–255.
- Nakayama, K., Nakayama, N., Davidson, B., Sheu, J. J., Jinawath, N., Santillan, A., Salani, R., Bristow, R. E., Morin, P. J., Kurman, R. J., Wang, T. L. & Shih, I.-M. (2006). *Proc. Natl Acad. Sci. USA*, **103**, 18739–18744.
- Nakayama, K., Nakayama, N., Wang, T. L. & Shih, I.-M. (2007). *Cancer Res.* **67**, 8058–8064.
- Parekh, S., Privé, G. & Melnick, A. (2008). *Leuk. Lymphoma*, **49**, 874–882.
- Perrakis, A., Morris, R. & Lamzin, V. S. (1999). *Nature Struct. Biol.* **6**, 458–463.
- Schubot, F. D., Tropea, J. E. & Waugh, D. S. (2006). *Biochem. Biophys. Res. Commun.* **351**, 1–6.
- Shen, H., Korutla, L., Champiaux, N., Toda, S., LaLumiere, R., Vallone, J., Klugmann, M., Blendy, J. A., Mackler, S. A. & Kalivas, P. W. (2007). *J. Neurosci.* **27**, 8903–8913.
- Stead, M. A., Rosbrook, G. O., Hadden, J. M., Trinh, C. H., Carr, S. B. & Wright, S. C. (2008). *Acta Cryst.* **F64**, 1101–1104.
- Stead, M. A., Trinh, C. H., Garnett, J. A., Carr, S. B., Baron, A. J., Edwards, T. A. & Wright, S. C. (2007). *J. Mol. Biol.* **373**, 820–826.
- Stebbins, C. E., Kaelin, W. G. Jr & Pavletich, N. P. (1999). *Science*, **284**, 455–461.
- Stogios, P. J., Chen, L. & Privé, G. G. (2007). *Protein Sci.* **16**, 336–342.
- Stogios, P. J., Downs, G. S., Jauhal, J. J., Nandra, S. K. & Privé, G. G. (2005). *Genome Biol.* **6**, R82.
- Wang, J., Rao, S., Chu, J., Shen, X., Levasseur, D. N., Theunissen, T. W. & Orkin, S. H. (2006). *Nature (London)*, **444**, 364–368.
- Yeasmin, S., Nakayama, K., Ishibashi, M., Katagiri, A., Iida, K., Purwana, I. N., Nakayama, N. & Miyazaki, K. (2008). *Clin. Cancer Res.* **14**, 1686–1691.